Use of miRNAs in Growth Hormone Deficiency (GHD)

Last updated: June 6, 2024
Sponsor: University of Parma
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hormone Deficiencies

Growth Hormone Deficiencies/abnormalities

Severe Short Stature

Treatment

N/A

Clinical Study ID

NCT06455956
821/2022/OSS/UNIPR
  • Ages 2-15
  • All Genders

Study Summary

This study aims at improving knowledge about the diagnosis of growth hormone deficiency (GHD) and treatment with growth hormone (GH), with the goal of providing information on the presence of new biomarkers, such as miRNAs, for diagnostic and therapeutic purposes, with the goal of establishing a personalized GH treatment scheme, optimizing resources, reducing costs, and improving outcomes.

Eligibility Criteria

Inclusion

Inclusion Criteria for aim 1:

  • Children with short stature and suspicion of GHD

  • Subjects with organic GH deficiency

Exclusion criteria for aim 1:

-Subjects with underlying genetic conditions and chronic diseases

Inclusion Criteria for aim 2-3-5:

  • patients having confirmed GHD enrolled for aim 1

  • patients with growth failure and born SGA (>4 yr of age)

  • patients with Noonan and Turner syndrome and growth failure

  • patients with short stature homeobox-containing gene deficiency (SHOXD) and growth failure

Inclusion Criteria for aim 4:

  • Isolated idiopathic prepubertal naive GHD subjects on long-acting versus daily GH therapy

Study Design

Total Participants: 400
Study Start date:
April 13, 2023
Estimated Completion Date:
March 01, 2026

Study Description

In 200 prepubertal and pubertal subjects with the suspicion of GHD, the levels of three specific circulating miRNas will be measured to establish whether they can be used for the diagnosis of GH deficiency. In subjects with isolated idiopathic GHD (IIGHD), short statured patients born SGA, Noonan and Turner syndromes, and SHOX deficiency, we will also assess the changes of the identified miRNAs before and after 3 months on GH therapy to verify an early growth prediction model for growth response at 12 months on treatment. Finally, we plan to identify any differences in these miRNAs at 3 months on treatment using daily GH versus weekly (long-acting) GH.

Connect with a study center

  • University of Parma

    Parma, Emilia Romagna 43121
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.